^
Association details:
Biomarker:No biomarker
Cancer:Gallbladder Cancer
Regimen: (cisplatin + gemcitabine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Neoadjuvant therapy (for gallbladder cancer only)…Other recommended regimens…Gemcitabine + cisplatin
Evidence Level:
Sensitive: B - Late Trials
Title:

Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

Published date:
11/07/2019
Excerpt:
Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer...Median OS in mGemOx was 9 months and 8·3 months in CisGem; p = 0·057 (hazard ratio = 0·78; 95% CI = 0·60-1·02). Restricted mean OS for follow-up limited to 30 months was 11·2 months (95% CI: 9·8–12·6) in mGemOx and 10·4 months (95% CI: 9·1–11·7) in CisGem....Numerically OS was better with mGemOx.
DOI:
doi.org/10.1016/j.ejca.2019.10.004
Evidence Level:
Sensitive: B - Late Trials
Title:

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

Published date:
04/08/2010
Excerpt:
...patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin...followed by gemcitabine...or gemcitabine alone...the median overall survival was 11.7 months among the 204 patients in the cisplatin-gemcitabine group and 8.1 months among the 206 patients in the gemcitabine group (hazard ratio, 0.64; 95% confidence interval, 0.52 to 0.80; P<0.001).
DOI:
10.1056/NEJMoa0908721